Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Descending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
99207-0260-01 99207-0260 Imiquimod Aldara 50.0 mg/g Immunotherapy Immunomodulator Dermatological Agent Topical Feb. 27, 1997 Dec. 31, 2015 No Longer Used
99207-0260-12 99207-0260 Imiquimod Aldara 50.0 mg/g Immunotherapy Immunomodulator Dermatological Agent Topical Feb. 27, 1997 June 30, 2022 No Longer Used
89141-0448-01 89141-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 2, 2010 Feb. 23, 2021 In Use
89141-0448-30 89141-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 31, 2016 Feb. 23, 2021 In Use
89141-0444-01 89141-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 2, 2010 Feb. 23, 2023 No Longer Used
89141-0444-30 89141-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 31, 2016 Feb. 23, 2023 No Longer Used
83858-0106-30 83858-0106 Dasatinib PHYRAGO 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0105-30 83858-0105 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0104-30 83858-0104 Dasatinib PHYRAGO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0103-60 83858-0103 Dasatinib PHYRAGO 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0101-60 83858-0101 Dasatinib PHYRAGO 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83831-0118-04 83831-0118 Cyclophosphamide Cyclophosphamide 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 1, 2024 In Use
83831-0117-02 83831-0117 Cyclophosphamide Cyclophosphamide 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 1, 2024 In Use
83831-0116-01 83831-0116 Cyclophosphamide Cyclophosphamide 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 1, 2024 In Use
83831-0112-01 83831-0112 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 28, 2024 In Use
83831-0111-01 83831-0111 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 28, 2024 In Use
83831-0105-01 83831-0105 Palonosetron Posfrea 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous July 30, 2024 In Use
83831-0103-16 83831-0103 Docetaxel DOCIVYX 160.0 mg/16mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0102-08 83831-0102 Docetaxel DOCIVYX 80.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0101-02 83831-0101 Docetaxel DOCIVYX 20.0 mg/2mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83774-0102-01 83774-0102 Azacitidine AZACITIDINE 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 14, 2024 In Use
83774-0101-12 83774-0101 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 27, 2024 In Use
83774-0100-60 83774-0100 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 27, 2024 In Use
83718-0000-01 83718-0000 Toripalimab-tpzi LOQTORZI 240.0 mg/6mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Oct. 27, 2023 In Use

Found 10,000 results in 2 millisecondsExport these results